Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH's Revised Conflict Of Interest Policy Will Close The Nemeroff Loophole, Collins Tells Congress

Executive Summary

New attention to a simmering scandal has increased scrutiny of NIH's effort to tighten up its existing conflict of interest policy and on a loophole the agency must be sure to eliminate

You may also be interested in...



NIH Conflict Of Interest Reg Attracts Criticism From Transparency Advocates

A new upgrade to the National Institutes of Health’s1995 regulations overseeing researcher conflict of interests is intended as “an insurance plan” against potential trouble downstream, NIH Director Francis Collins says. But a key change in the final rule compared to an earlier proposal is attracting criticism from transparency advocates.

NIH Conflict Of Interest Reg Attracts Criticism From Transparency Advocates

A new upgrade to the National Institutes of Health’s1995 regulations overseeing researcher conflict of interests is intended as “an insurance plan” against potential trouble downstream, NIH Director Francis Collins says. But a key change in the final rule compared to an earlier proposal is attracting criticism from transparency advocates.

NIH Conflict Of Interest Reg Aims To Bolster Public Trust As Links To Industry Flourish

Upgrade of the 1995 regs is "an insurance plan" against potential trouble downstream, NIH Director Collins says, but some advocacy groups wanted broader disclosure.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel